Login
About the projectSP3 - Health Impact    August 22, 2017  English (United States) English (United Kingdom)
Overview of SP3: Relationships between transport related PM and health
 
This subproject will evaluate the health impacts of transport related emissions. It will be based on both existing studies and on the recently funded European Study of Cohorts for Air Pollution Effects (ESCAPE). This SP will develop source specific concentration response functions suitable for application in health impact assessments 

The ESCAPE study includes 33 cohorts, subdivided in four major groups:
1. Birth cohorts on pregnancy outcomes, allergy and asthma, and neuro developmental effects
2. Cohorts on adult respiratory disease outcomes
3. Cohorts on adult cardiovascular disease outcomes
4. ohorts on cancer incidence and mortality outcomes.

The collaboration in ESCAPE represents a large investment in ongoing cohort studies in Europe, from a wide range of local, national and international funds. ESCAPE adds assessment of air pollution exposure to these studies, with an emphasis on spatial contrasts in PM and NOx from road transport. Measurements of PM2.5, PM10 and NOx are being conducted 22 different areas; measurements of NOx only are being conducted in an additional 17 areas. PM measurements are being conducted on 20 different sites in each area to investigate spatial contrasts while NOx is measured at 40 sites per area.

With the new information generated in TRANSPHORM and ESCAPE on exposure response functions, for long and short term effects, the impacts of transport related PM pollution on health can be assessed. It should be noted that the effects of long-term exposure (for which we will have new C-R functions) are by far the dominant ones in terms of public health overall. However, TRANSPHORM will also develop new functions for acute exposures providing a unique comprehensive treatment of short and long term effects resulting from PM air pollution.

Contact: Bert Brunekreef (SP leader), Dimosthenis Sarigiannis (SP deputy leader)
 
 
Work packages and their objectives
 
To quantify the relationship between transport related ambient PM air pollution and pregnancy outcomes

To quantify the relationship between transport related ambient PM air pollution and childhood disease and development
To quantify the relationship between transport related ambient PM air pollution and chronic bronchitis and COPD.

To quantify the relationship between transport related ambient PM air pollution and the incidence of asthma.
To quantify the relationship between transport related ambient PM air pollution and various cardiovascular disease morbidity.

To quantify the relationship between transport related ambient PM air pollution and blood pressure and prevalence of hypertension.

To quantify the relationship between transport related ambient PM air pollution and incident coronary events.
To quantify the relationship between transport related ambient PM air pollution and mortality.

To quantify the relationship between transport related ambient PM air pollution and lung cancer incidence.

To quantify the relationship between transport related ambient PM air pollution and Non-accidental, cardiovascular and respiratory disease mortality.
To substantially improve on the existing HIA methodology (e.g. as in CAFE HIA / Cost-Benefit Analysis) and so to develop the HIA methodology to assess the health impact of transport related PM in Europe. This includes methods for baseline scenarios, but especially for changes in population exposure following changes in policies or measures that affect transport emissions.

To propose relevant C-R functions based on the new TRANSPHORM analyses of the ESCAPE cohorts and exposure estimates from SP2.

To estimate background rates of health outcomes and life expectancy benefits of reduced PM air pollution.

To estimate the internal dose of particulate matter fractions and specific chemical species present on the different PM size fractions and linking C-R functions to real exposure.

To develop models for estimation of population health risk and aggregate burden of disease across health endpoints.
 
 
SP3 partner list
 
 
 
SP3 email list
 
Hover here, then click toolbar to edit content
 
 
 Copyright 2010 by NILU   Terms Of Use  Privacy Statement